Brodeur 1988.

Methods	Randomised controlled crossover trial of levodopa versus placebo Dropouts/withdrawals: Total N of 6, no premature discontinuations
Participants	Included/analysed: 6/6 Demographics: 3 male, age 51.3 years Diagnosis: primary RLS according to clinical evaluation, nocturnal awakenings and daytime sleepiness Setting: 1 centre in Canada Baseline: PLMSI (using PSG) 38.2 ± 12.7
Interventions	Intervention: fixed dose of 100 mg/25 mg levodopa/benserazide twice daily (1hour before, 3 hours after going to bed) for 14 days Control: fixed dose of placebo capsules twice daily (1hour before, 3 hours after going to bed) for 14 days Washout for 1 week between treatment periods
Outcomes	Objective quality of sleep: change in sleep parameters (TST), PLMSI (using PSG) Safety: Number of dropouts due to adverse events
funding source	The study was supported by the Medical Research Council of Canada, the Fonds de la recherche en santé du Québec and the Fond pour la formation de chercheurs et l'aide à la recherche du Québec.
Notes	TST: total sleep time; PSG: polysomnography
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Insufficient information.
Allocation concealment?	Unclear risk	Insufficient information.
Blinding? All outcomes	Unclear risk	No information concerning blinding of staff, examiners, polysomnography analysis.
Incomplete outcome data addressed? All outcomes	Low risk	All patients were included in analyses.
Free of selective reporting?	Unclear risk	No outcomes prespecified.
Free of other bias?	Low risk	Low indication of bias.